NautaDutilh advises the shareholders of SUAZIO on the sale of their shares to NAMSA
NautaDutilh advised the shareholders of SUAZIO, a EU-based marketing consultancy specialising in the commercialization of new medical devices, on the sale of their shares to NAMSA, a world-leading MedTech Contract Research Organization (CRO).
This deal takes SUAZIO up multiple levels for winning new contracts, data gathering, and accelerating global growth. SUAZIO is the seventh add-on acquisition for NAMSA since the group was acquired by global investment firm ARCHIMED’s MED Platform I fund in September 2020. The Gorski founding family and current and former management contributed to funding the SUAZIO deal and continue to own a substantial equity stake in NAMSA. Four of the US-headquartered group’s seven acquisitions were European-based companies.
"We wish SUAZIO a successful strategic partnership with NAMSA, allowing them to extend their reach within the MedTech ecosystem. Many thanks to Christophe Van der Linden for his trust in us and the pleasant collaboration. Congratulations to all parties involved." says Philippe Remels who led our transaction team together with counsel Christophe Wathion.
The team further consisted of Ken Lioen, Aurélien Lenaerts (Tax) and Louisa Vandepitte (Corporate M&A). Morgan, Lewis & Bockius provided advice on the US aspects of the transaction.